Advisory committees nominations
This article was originally published in The Tan Sheet
Executive SummaryAny firms interested in nominating industry representatives to serve on the Center for Drug Evaluation and Research's public advisory committees must notify FDA by July 9, the agency says. FDA announces in the Federal Register June 8 industry representatives may serve as nonvoting members on public advisory committees such as the Nonprescription Drugs Advisory Committee and the Advisory Committee for Reproductive Health Drugs...
You may also be interested in...
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.
Medicaid programs are essentially getting Humira for free, in large part because of price inflation rebates, according to estimates by Bernstein analysts. Legislation pending in the US Senate wants to bring that dynamic to Medicare.